Eli Lilly's diabetes drug Mounjaro is set to be included in China's national health insurance reimbursement list, boosting accessibility but with potential revenue impact from pricing adjustments.

In 2021-2022, diabetes treatment costs in the U.S. totaled $153.2 billion, driven largely by Medicare and private insurance coverage, according to AHRQ MEPS data.

Eli Lilly's Mounjaro joins China's national health insurance list for type 2 diabetes, enhancing accessibility amid pricing adjustments. Related diabetes therapies and market impacts examined.

AdvaMed responds to CMS 2026 payment rule, stressing patient access to diabetes and prosthetic supplies amid competitive bidding concerns.

CCS’s AI-driven PropheSee™ platform significantly improves CGM adherence in Medicare diabetes patients, saving $10M+ and advancing preventive chronic care.

Novo Nordisk applies for FDA approval of oral anti-obesity drug following Eli Lilly's clinical success, intensifying competition in the GLP-1 diabetes and weight loss market.

Explore how Medicare covers diabetes treatments and costs including Metformin and other diabetic supplies under Parts A, B, C, and D. Understand cost factors like premiums and deductibles.

A study finds that nearly 65% of users of weight loss drugs like Ozempic quit due to high costs and limited insurance coverage. Understanding the challenges in affordability and access is crucial to improve health outcomes.

Recent Medicare changes now allow more seniors to access continuous glucose monitors, improving diabetes management at low cost.